Triamterene

Introduction Overview

Generic Name

triamterene

Brand Name

Dyrenium

Dosage Form

Oral capsules

Drug Class

Potassium-sparing diuretics

Pharmacokinetics

Absorption:
Triamterene is administered orally and exhibits good absorption from the gastrointestinal tract, particularly when taken with food which aids in minimizing gastrointestinal irritation. Upon ingestion, triamterene is absorbed into the bloodstream where it begins to exert its diuretic effect by acting on the distal tubules of the nephron. The presence of food enhances the bioavailability and can reduce potential stomach upset, which is why it is recommended to take after meals.

Distribution:
Once absorbed, triamterene distributes moderately within the body fluids and tissues, primarily targeting renal tubular cells in the distal convoluted tubules and collecting ducts of the kidneys. It has a moderate volume of distribution and is highly protein-bound in plasma, primarily to albumin. This distribution profile contributes to its efficacy in altering electrolyte fluxes without systemic toxicity. It crosses the placenta and is found in minimal amounts in breast milk, thus contraindicating its use during breastfeeding.

Metabolism:
Triamterene undergoes hepatic metabolism involving oxidative processes mediated by cytochrome P450 enzymes, resulting in metabolites such as 4-hydroxytriamterene, among others. These metabolites possess some degree of pharmacologic activity, contributing to the overall diuretic effect. The metabolic pathways affect the drug's duration of action and potential interactions with other substances metabolized via the same enzymatic systems.

Elimination:
The drug and its metabolites are primarily excreted via renal elimination, with a smaller fraction excreted in the feces. The elimination half-life is approximately 4 to 12 hours, depending on renal function. Impaired kidney function significantly reduces clearance leading to drug accumulation and increased risk of hyperkalemia. Therefore, dosage adjustments are necessary in patients with renal impairment. The drug's elimination can be influenced by concomitant medications and patient-specific factors such as age and comorbidities.

Dosage Forms

Available Dosage Forms:
Triamterene is available primarily as oral capsules. Common capsule strengths include 50 mg and 100 mg formulations. It is also combined in fixed-dose formulations with thiazide diuretics for enhanced therapeutic effect but as a single agent, capsules are standard.

Dosages for Adults and Adolescents:
Typical dosing for edema or ascites begins with 100 mg orally twice daily after meals. The dose can be titrated individually based on clinical response, with a maximum recommended dose of 300 mg per day. The time to maximum therapeutic effect may require several days, necessitating careful dose adjustments. When used in combination with other diuretics or antihypertensives, initial doses should be conservative, aiming to minimize electrolyte disturbances.

Specific Patient Populations:
Use in the elderly requires caution due to altered pharmacokinetics and increased risk for hyperkalemia. Triamterene is contraindicated in children under 18 years due to lack of safety data. In patients with impaired renal or hepatic function, dosing should be adjusted or avoided due to reduced clearance and increased risk of adverse effects. Pregnancy use is generally avoided unless benefits outweigh potential fetal risk. Breastfeeding is not recommended during triamterene therapy as the drug may pass into breast milk.

Mechanism Of Action

Triamterene is a potassium-sparing diuretic that primarily acts on the distal convoluted tubules and collecting ducts of the nephron to inhibit sodium reabsorption. It exerts its effect by directly blocking the epithelial sodium channels (ENaC) on the luminal membrane of renal tubular cells, which decreases sodium reuptake into the cells. The reduced sodium uptake diminishes the electrochemical gradient necessary for potassium secretion, thereby conserving potassium in the body.

At the cellular level, triamterene acts independently of aldosterone, distinguishing it from aldosterone antagonists like spironolactone. This direct inhibition of sodium channels results in a reduction of water reabsorption associated with sodium movement, promoting natriuresis and diuresis while minimizing potassium loss. This unique mechanism helps prevent hypokalemia—a common limitation of many other diuretics.

Biochemically, triamterene’s blockade of ENaC affects downstream cellular signaling and electrolyte balance, contributing to the stabilization of serum potassium levels. Clinical implications include reduced risk of hypokalemia-induced cardiac arrhythmias and muscular symptoms, making it especially valuable in patients at risk for low potassium.

Comparative studies demonstrate that triamterene’s mechanism is complementary to thiazide and loop diuretics, which increase potassium excretion. Hence, triamterene is often used concomitantly to offset potassium loss. Clinical trials have established its efficacy in managing edema with fewer electrolyte disturbances compared to non-potassium-sparing agents.

Pharmacological Actions

Direct inhibition of epithelial sodium channels in renal distal tubules and collecting ducts.
Potassium-sparing diuretic effect preventing hypokalemia.
Promotes natriuresis and diuresis by decreasing sodium and water reabsorption.
Does not antagonize aldosterone but acts independent of aldosterone pathways.
Reduces fluid retention associated with congestive heart failure, cirrhosis, and nephrotic syndrome.
Helps maintain electrolyte balance, reducing risk of arrhythmias caused by potassium imbalance.
Modulates renal tubular function to decrease edema without substantial potassium loss.
Has minimal impact on systemic hemodynamics compared to other diuretics.
Potential antioxidant properties through some metabolites under study.
Slows progression of secondary hyperaldosteronism by limiting sodium retention.

Therapeutic Or Clinical Uses

Treatment of edema associated with congestive heart failure.
Management of fluid retention in liver cirrhosis.
Reduction of edema caused by nephrotic syndrome.
Edema management related to corticosteroid therapy.
Use as adjunctive therapy with other diuretics to prevent hypokalemia.
Control of ascites in patients with liver disease.
Treatment of hypertension in combination with other antihypertensive agents.
Prevention of potassium depletion during prolonged diuretic therapy.
Adjunct treatment in patients with hyperaldosteronism-related edema.
Supportive therapy for patients at risk of electrolyte imbalance due to diuretics.

Side Or Adverse Effects

Hyperkalemia, manifesting as nausea, weakness, arrhythmias, and muscle paralysis.
Gastrointestinal disturbances including nausea and diarrhea.
Dizziness and headache due to electrolyte or volume changes.
Dry mouth and general fatigue or weakness.
Signs of kidney stones, such as back or side pain, painful urination, and cloudy urine.
Hypersensitivity reactions such as rash or hives.
Jaundice indicating potential hepatic involvement.
Altered heart rhythms including slow, fast, or irregular heartbeat.
Reduced urine output or signs of acute kidney injury.
Rare reports of blood dyscrasias leading to easy bruising or bleeding.
Photosensitivity increasing risk of sunburn.
Potential impairment of mental alertness or reaction time.
Electrolyte imbalances with prolonged or high-dose use.
Risk of dehydration and hypotension when combined with other diuretics.
Potential interactions leading to lithium toxicity when coadministered.

Precautions

Monitor serum potassium regularly to avoid hyperkalemia.
Avoid use in patients with severe renal or hepatic impairment.
Do not coadminister with potassium supplements or other potassium-sparing agents.
Use cautiously in patients with diabetes and cardiac disease.
Avoid salt substitutes containing potassium during therapy.
Dose adjustment or discontinuation may be needed with impaired kidney function.
Avoid alcohol as it can increase central nervous system side effects.
Caution with concurrent use of NSAIDs which may reduce diuretic efficacy.
Avoid excessive sun exposure and use sunscreen due to photosensitivity risk.
Careful monitoring during pregnancy; weigh benefits against fetal risks.
Contraindicated in patients unable to urinate or with urinary retention.
Do not use in pediatric patients as safety and efficacy not established.
Potential for drug interactions affecting blood glucose control in diabetics.
Alert patients to avoid dehydration especially in hot weather or with exercise.
Inform healthcare providers before surgical procedures to manage electrolyte status.

Warnings

Contraindicated in patients with hyperkalemia or high serum potassium levels.
Avoid in severe kidney disease or urinary retention.
Risk of life-threatening hyperkalemia especially in elderly and those with renal impairment.
Do not combine with potassium supplements, potassium-containing salt substitutes, or other potassium-sparing diuretics.
Can impair thinking or reactions; avoid driving or hazardous activities until effect known.
Avoid alcohol intake due to enhanced side effects.
May cause photosensitivity; use sun protection to prevent severe sunburn.
Excessive fluid loss can lead to dehydration and electrolyte imbalances.
Close monitoring required during concurrent use with NSAIDs or lithium.
Pregnancy category risk: potential fetal harm; only use when benefits outweigh risks.
Not recommended during breastfeeding due to potential drug excretion in milk.
Patients with liver disease need close observation due to altered metabolism.
Symptoms of overdose include nausea, vomiting, arrhythmias, and muscle weakness requiring emergency care.
Increased risk of kidney stone formation necessitates monitoring.
Signs of allergic reactions require immediate medical intervention.

Contraindication

Known hypersensitivity to triamterene or any component of the formulation.
Severe renal impairment or anuria (inability to urinate).
Severe hepatic impairment or liver failure.
Hyperkalemia or elevated serum potassium at baseline.
Concomitant use with potassium supplements or potassium-sparing diuretics like amiloride or spironolactone.
Patients with urinary retention or obstruction.
Pediatric patients under 18 years due to insufficient safety data.
Pregnancy unless clearly necessary as judged by a physician.
Known hypersensitivity to similar potassium-sparing agents.
Conditions associated with risk of developing hyperkalemia such as Addison’s disease without proper control.
Patients receiving lithium therapy without appropriate monitoring.
Use during breastfeeding due to potential adverse effects on infant.
Concomitant use with other agents that may increase potassium levels without close monitoring.
Severe dehydration or electrolyte imbalance before treatment initiation.
Metabolic acidosis or uncompensated adrenal insufficiency.

Drug Interactions

Concomitant use with potassium supplements increases risk of hyperkalemia.
Use with other potassium-sparing diuretics such as amiloride, spironolactone, or eplerenone increases hyperkalemia risk.
NSAIDs (e.g., ibuprofen, naproxen, celecoxib) may reduce diuretic efficacy and promote renal impairment.
Lithium levels can increase with triamterene due to reduced renal clearance, risking lithium toxicity.
Concurrent insulin or oral hypoglycemic drugs may require dose adjustments due to altered potassium handling.
ACE inhibitors and angiotensin receptor blockers increase risk of hyperkalemia when combined.
Other antihypertensive drugs may enhance hypotensive effects necessitating dosage adjustments.
Drugs affecting renal function can alter triamterene elimination and plasma levels.
Use with digoxin requires caution due to risk of arrhythmias potentiated by electrolyte disturbances.
Avoid concomitant use with drugs causing electrolyte imbalances, such as corticosteroids or amphotericin B.
Concomitant use with nondepolarizing muscle relaxants may potentiate neuromuscular blockade.
Combination with CYP450 inhibitors may alter triamterene metabolism leading to toxicity.
Avoid combination with agents that increase serum potassium unless under strict monitoring.
Interactions with diuretics that cause hypokalemia are beneficial but require dose balancing.
Use with caution alongside drugs metabolized by kidney or affecting kidney tubular function.

Preparations Of The Drug

Oral capsules of triamterene in 50 mg strength.
Oral capsules of triamterene in 100 mg strength.
Fixed-dose combinations with hydrochlorothiazide available in variable strengths (not covered here as monotherapy focus).
Standard oral formulation administered twice daily after meals.
Available as branded product Dyrenium.
Packaging typically includes child-resistant bottles to ensure safe storage.
Stable at room temperature, with storage instructions to keep away from moisture and heat.
Single-agent preparations for oral use only; no injectable or topical forms commercially available.
Labels include warnings about hyperkalemia risk and patient counseling information.
Prescribed primarily for adult use; off-label formulations or pediatric forms are not marketed.
Bulk powder or compounding forms rarely used outside specialized pharmacy settings.
May be available in generic capsule formulations varying by manufacturer.
Accompanied by patient information leaflets highlighting dosing, precautions, and monitoring.
Not available as over-the-counter; prescription required for legal dispensing.
Commercially manufactured using pharmaceutical-grade excipients ensuring consistent bioavailability.